It’s crucial to develop pharmacotherapeutic agents for epilepsy associated with pathogenic SCN2A mutation, which function primarily by amplifying resurgent and/or persistent currents, and may get involved in selective suppression of the aberrantly enhanced resurgent and/or persistent currents. Here, SCN2A is linked to epilepsy.